No Detail Found!

Progress in Oncolytic Virotherapy for Cancer and Future Directions Non-Small Cell Lung

Author(s)
Mohamed Aalilil Faculty of Medicine, Ala-Too International University, Bishkek, Kyrgyzstan
Prasant Yadav Department of Microbiology, ESIC Hospital and PGIMSR, Basaidarapur, New Delhi, India
Amar Chandra Sharma Department of Trauma Surgery, King George Medical University, Lucknow, India
Amit Verma Division of Diagnostic Innovation, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United State of America
Mirza Masroor Ali Beg Faculty of Medicine, Ala-Too International University, Bishkek, Kyrgyzstan
Abstract
Oncolytic virotherapy (OV) represents an emerging therapeutic modality for non-small cell lung cancer (NSCLC), leveraging viruses to selectively target tumor cells and stimulate anti-tumor immunity. This review synthesizes evidence from key studies to evaluate the current landscape and future directions of OV in NSCLC. We systematically analyzed six pivotal studies investigating diverse oncolytic virus platforms, including Newcastle Disease Virus (NDV), pelareorep (reovirus), M1 virus, coxsackieviruses (CVA11 and CVB5) and engineered HSV-1 (RP2/RP3). The analysis encompassed both preclinical investigations and clinical trials to assess therapeutic efficacy, mechanisms of action and limitations. The evidence reveals a field marked by both promising breakthroughs and significant challenges. The most compelling clinical success comes from engineered HSV-1 (RP2/RP3) in combination with stereotactic body radiation therapy (SBRT) and pembrolizumab, demonstrating a 33.3% objective response rate and robust immune activation. In contrast, pelareorep combined with chemotherapy failed to show survival benefit, highlighting the critical importance of combination partner selection. Preclinical studies showed exceptional promise with coxsackieviruses achieving complete tumor regression and the M1 virus identifying MXRA8 as a predictive biomarker. However, these findings are tempered by translational challenges, including the gap between immunocompromised models and human trials and safety concerns regarding combination strategies that potentiate DNA damage. Oncolytic virotherapy demonstrates significant potential for NSCLC treatment, particularly as an immunepriming modality in rationally designed combinations. Future success requires strategic focus on immunologically congruent combinations, biomarker-driven patient selection and innovative trial designs to bridge the divide between preclinical promise and clinical application. The field must learn from both successes and failures to realize the full potential of these novel therapeutic agents.
Publication Details
Page(s) 98-103
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 1, Year: 2026

Request the full text from PASTIC

Keywords
Non-small Cell Lung Cancer, Next-Generation Cancer Therapies, Oncolytic Viruses, TumorTargeting Viruses, Oncolytic Virotherapy, cancer immunotherapy
References
Cancer Society American .2022 .. Accessed, : .
Cancer Society American .2022 .Key statistics for lung cancer. Accessed, : .
Comprehensive Cancer Network National .2023 .Clinical practice guidelines in oncology. , : .
Lawler S.E. . .Oncolytic viruses in cancer treatment: a review. ” JAMA Oncology, 2(2016) : 841-849.
Russell S.J. . .Oncolytic virotherapy. Nature Biotechnology, 30(2012) : 658-670.
Balasubramanian A. .2025 .Effects of CVA21, an oncolytic virus, in combination with pembrolizumab on immunogenicity and the tumor microenvironment in advanced NSCLC: a phase I/II trial. Clinical Cancer Research, 25(22) : 1078-0432.
Song D. . .Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. ” Signal Transduction and Targeted Therapy, 7(2022) : 100.
Garcia-Carbonero R. . .Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. ” Journal for ImmunoTherapy of Cancer, 5(2017) : 71.
Bradbury P.A. .2018 .Canadian Cancer Trials Group (CCTG) IND211: a randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic nonsmall cell lung cancer receiving standard salvage therapy. ” Lung Cancer, 03 : 142-148.
Hu L. .2015 .Oncolytic Newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy. American Journal of Cancer Research, 5(12) : 3612-3623.
Patel M.R. .2019 .JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. ” Cancer Gene Therapy, 26 : 411-418.
Guan J. .2023 .A phase 2 study of in situ oncolytic virus therapy and stereotactic body radiation therapy followed by pembrolizumab in metastatic non-small cell lung cancer. International Journal of Radiation Oncology, 08(2024) : 1531-1540.
Ribas A. .2017 .Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell, 08(2017) : 1109-1119.
Annels N.E. .2019 .Phase I trial of an ICAM-1-targeted immunotherapeutic Coxsackievirus A21 (CVA21) as an oncolytic agent against non-muscle-invasive bladder cancer. ” Clinical Cancer Research, 18(19) : 1078-0432.
Mahalingam D. .2018 .A phase II study of pelareorep (REOLYSIN®) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma. ” Cancers, 10 : 160.
Khuri F.R. . .A controlled trial of intratumoral ONYX015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Medicine, 6(2000) : 879-885.
Sakamoto A. . .Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer. Scientific Reports, 13(2023) : 5924.
Cui B. . .Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNAdamage response inhibitors. ” Signal Transduction and Targeted Therapy, 8(2023) : 366.
Lawler S.E. .2064 .Oncolytic viruses in cancer treatment: a review. ” JAMA Oncology, 3(2017) : 841-849.
Lord C.J.,Ashworth A. .2017 .PARP inhibitors: synthetic lethality in the clinic. ” Science, 355(6330) : 1152-1158.
Slamon D.J. .2001 .Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. ” The New England Journal of Medicine, 344(11) : 783-792.
Mok T.S. .2009 .Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. ” The New England Journal of Medicine, 361(10) : 947-957.
Rosenfeld M.R. .2010 .A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. ” Neuro-Oncology, 12(10) : 1071-1077.
Andtbacka R.H. .2014 .Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. ” Journal of Clinical Oncology, 58(25) : 2780-2788.
0

Citations

0

Downloads

16

Views